The novel investigational oral antibiotic gepotidacin was efficacious and safe for the treatment of uncomplicated urinary tract infections, with activity against common uropathogens. Gepotidacin, a ...

Review shows lower odds of symptomatic UTI episodes in children with history of recurrent UTIs with nitrofurantoin, cranberry. (HealthDay News) — For children with a history of recurrent urinary tract ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Gepotidacin -- a ...

When it comes to treating urinary tract infections (UTIs), antibiotics continue to be the number one go-to treatment. Most ...

Please provide your email address to receive an email when new articles are posted on . Gepotidacin is the first in a new class of oral antibiotics for uUTIs in nearly 30 years. The approval was ...

The PDUFA target date was set for March 26, 2025. The Food and Drug Administration has granted Priority Review to gepotidacin for the treatment of female adult and adolescent patients aged 12 years ...

The FDA approved oral gepotidacin (Blujepa) for uncomplicated urinary tract infections (UTIs) in women and girls ages 12 years and up, GSK announced on Tuesday. Results of two phase III trials -- ...

The first new type of antibiotic developed in more than 20 years to treat urinary tract infections (UTIs) appears to be so effective that the pharmaceutical company stopped testing and will soon ...

Wendy Cheng, PhD, MPH, discusses how the largest unmet needs in the landscape of urinary tract infections (UTIs) include addressing antimicrobial resistance, improving treatment options for resistant ...

Cranberry products (compared with the control group) and nitrofurantoin (compared with the control, trimethoprim-sulfamethoxazole, or trimethoprim groups) led to lower odds of symptomatic UTI episodes ...